Tarsus Retained Earnings Total Equity from 2010 to 2024
| TARS Stock | USD 50.84 1.18 2.38% |
Retained Earnings Total Equity | First Reported 2010-12-31 | Previous Quarter -97.9 M | Current Value -102.8 M | Quarterly Volatility 28.9 M |
Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 6.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 35.81, Dividend Yield of 0.0 or PTB Ratio of 3.17. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
Tarsus | Retained Earnings Total Equity |
Latest Tarsus Pharmaceuticals' Retained Earnings Total Equity Growth Pattern
Below is the plot of the Retained Earnings Total Equity of Tarsus Pharmaceuticals over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Tarsus Pharmaceuticals' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tarsus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Retained Earnings Total Equity | 10 Years Trend |
|
Retained Earnings Total Equity |
| Timeline |
Tarsus Retained Earnings Total Equity Regression Statistics
| Arithmetic Mean | (47,826,516) | |
| Coefficient Of Variation | (60.47) | |
| Mean Deviation | 22,126,825 | |
| Median | (32,845,000) | |
| Standard Deviation | 28,920,474 | |
| Sample Variance | 836.4T | |
| Range | 75.9M | |
| R-Value | (0.73) | |
| Mean Square Error | 425.9T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | (4,695,359) | |
| Total Sum of Squares | 11709.5T |
Tarsus Retained Earnings Total Equity History
About Tarsus Pharmaceuticals Financial Statements
Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Retained Earnings Total Equity | -97.9 M | -102.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.